0001140361-17-041378.txt : 20171107 0001140361-17-041378.hdr.sgml : 20171107 20171107160708 ACCESSION NUMBER: 0001140361-17-041378 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171103 FILED AS OF DATE: 20171107 DATE AS OF CHANGE: 20171107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Abdun-Nabi Daniel CENTRAL INDEX KEY: 0001380187 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 171183434 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DRIVE STREET 2: SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 4 1 doc1.xml FORM 4 X0306 4 2017-11-03 0 0001367644 Emergent BioSolutions Inc. EBS 0001380187 Abdun-Nabi Daniel 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 1 1 0 0 President & CEO Common Stock 2017-11-03 4 M 0 11508 22.03 A 215642 D Common Stock 2017-11-03 4 S 0 11508 42.50 D 204134 D Common Stock 2017-11-03 4 M 0 20000 14.44 A 224134 D Common Stock 2017-11-03 4 S 0 20000 42.92 D 204134 D Common Stock 1000 I By Son Stock Option (Right to Buy) 22.03 2017-11-03 4 M 0 11508 0 D 2018-03-14 Common Stock 11508 0 D Stock Option (Right to Buy) 14.44 2017-11-03 4 M 0 20000 0 D 2019-03-12 Common Stock 20000 41906 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.47 to $42.78, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.70 to $43.00, inclusive. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Consists of an option granted under the company's stock incentive plan as amended and restated. The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. /s/ Eric Burt, Attorney-in-fact 2017-11-07